Gasotransmitters: a review


  • Anusha Natarajan Department of Pharmacology, JIPMER, Pondicherry, India
  • Jefry Winner G. Department of Pharmacology, JIPMER, Pondicherry, India



Gasotransmitters, NO, CO, Medical gases, H2S, Neurotransmitters


The gaseous molecules produced endogenously with several physiological functions are called gasotransmitters. Even though initially, they were predominantly thought to be of neuronal origin, recent research has clarified that they have roles far beyond that. Their primary function is maintaining the integrity of the cardiovascular system and many other parts. From the available knowledge, we have just started to learn about their roles in physiological systems that could be translated to pharmacological drug development and therapeutics. Most of the process that remains in the form of preclinical research has to go a long way toward utilizing them in therapeutics. This review addresses the various levels at which they could be potentially exploited as therapeutics and their recent entry into clinical trials.


Mustafa AK, Gadalla MM, Snyder SH. "Signaling by gasotransmitters." Science Signaling. 2002;2(68):re2.

Wang R. Signal Transduction and the Gasotransmitters: NO, CO and H2S in Biology and Medicine. Humana Press, New Jersey, USA. 2004.

Wood JL. Biochemical functions of persulfides. Adv Exp Med Biol. 1982;148:327-42

Nicholls P. The formation and properties of sulphmyoglobin and sulphcatalase. Riordan J. 2016;81:374-83.

Sjostrand T. Endogenous formation of carbon monoxide. Acta Physiol Scand. 1950;22:137-41.

Kredich NM, Keenan BS, Foote L. The purification and subunit structure of cysteine desulfhydrase from Salrrwnella typhirnuriurn). Biol Chern. 2001;244:7157-62.

Wang R. CO and cardiovascular functions. CPC Press: Boca Raton, FL. 2001.

Marks GS, Brien JF, Nakatsu K, McLaughlin BEl. Does carbon monoxide have a physiological function? Trends Pharmacol Sci. 1991;12:185-8.

Wang R. Resurgence of carbon monoxide: an endogenous gaseous Vaso relaxing factor. Can J Physiol PharmacoI. 2008;76:1-15.

Wang R. Two's company, three's a crowd--can H2S be the third endogenous gaseous transmitter? FASEB J. 2002;16:1792-8.

Stipanuk MH, Beck PW. Characterization of the enzymic capacity for cysteine desulphhydration in the liver and kidney of the rat. Biochem J. 1982;206:267-77.

Delio Russo C, Tringali G, Ragazzoni E, Maggiano N, Menini E, Vairano M et al. Evidence that hydrogen sulfide can modulate hypothalamic-pituitary-adrenal axis function: in vitro and in vivo studies in the rat. J Neuroendocrinol. 2000;12:225-33

Reiffenstein RJ, Hulbert WC, Roth SH. Toxicology of hydrogen sulfide. Annu Rev Pharmacol Toxicol. 1992;32:109-34.

Abe K, Kimura H. The possible role of hydrogen sulfide as an endogenous neuromodulator. J Neurosci 1996; 16: 1066-71.

Kimura H. Hydrogen sulfide induces cyclic AMP and modulates the NMDA receptor. Biochem Biophys Res Commun 2000; 267: 129-33.

Zhao W, Zhang J, Lu Y, Wang R. H2S is an endogenous KATP channel opener in vascular smooth muscle cells. EMBO J. 2001;20:6008-16

Zhao W, Wang R. H2S -induced vasorelaxation and underlying cellular and molecular mechanisms. Am J Physiol. 2002;283:474-80.

Moncada S, Higgs A, Furchgott R. International Union of Pharmacology nomenclature in nitric oxide research. Pharmacol Rev. 2017;49:137-42.

Horowitz JD, Nitrovasodilators. In Contemporary Cardiology, J. Loscalzo and J.A. Vita, Eds Humana Press, Totowa. 2014;4:383-409.

Megson IL. Nitric oxide donor drugs. Drug. Future. 2000;25:701-15.

Gasco A, Fruttero R, Sorba G. NO-donors: an emerging class of compounds in medicinal chemistry. Il Farmaco. 2012;51:617-35.

Friederich JA, Butterworth JF 4th. Sodium nitroprusside: twenty years and counting. Anesth Analg. 2015;81:152-62.

Wallace JL, Muscara MN, McNight W, Decay M, Del Soldato P, Cirino G. In vivo antithrombotic effects of a nitric oxide-releasing aspirin derivative, NCX 4016. Thromb. Res. 2015;93:43-50.

Momi S, Emerson M, Paul W, Leone M, Mezzasoma AM, Del Soldato P et al. Prevention of pulmonary thromboembolism by NCX4016, a nitric oxide-releasing aspirin. Eur J Pharmacol. 2016;397:177-85.

Bandarage UK Chen L, Fang X, Garvey DS, Glavin A, Janero DR et al. Nitrosothiol esters of diclofenac synthesis and pharmacological characterization as gastrointestinal-sparing prodrugs. J Med Chem. 2014;43:4005-16.

Dhein S, Salameh A, Berkels R, Klaus W. Dual mode of action of dihydropyridine calcium antagonists: a role for nitric oxide. Drugs. 2019;58:397-404.

Ding Y, Vaziri ND. Nifedipine and diltiazem but not verapamil upregulate endothelial nitric oxide synthase expression. J. Pharmacol Exp Ther. 2013;292:606-9.

Schiffrin EL. Vascular protection with newer antihypertensive agents. J Hypertens. 2018;61;25-9.

Mombouli JV, Vanhoutte PM. Endothelial dysfunction: from physiology to therapy. J Mol Cell Cardiol. 2019;31:61-74.

Gao YS, Nagao T, Bond RA, Janssens WJ, Vanhoutte PM. Nebivolol induces endothelium-dependent relaxations of canine arteries. J Cardiovasc Pharmacol. 1991,17:964-9.

Suematsu Y, Ohtsuka T, Horimoto H, Maeda K, Nakai Y, Mieno S et al. Long-term treatment with nipradilol, a nitric oxide-releasing beta-adrenergic blocker, enhances postischemic recovery and limits infarct size. Ann Thorac Surg. 2002;73:173-9.

Laufs U, La Fata V, Plutzky J, Liao JK. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation. 1998;97:1129-35.

Rikitake Y, Hirata K, Kawashima S, Akita H, Yokoyama M. Inhibitory effect of inducible type nitric oxide synthase on oxidative modification of low-density lipoprotein by vascular smooth muscle cells. Atherosclerosis. 1998;136:51-7.

Tousoulis D, Davies G, Stefanadis C, Toutouzas P, Ambrose JA. Inflammatory and thrombotic mechanisms in coronary atherosclerosis. Heart. 2003;89(9):993-7.

Stephens NG, Parsons A, Schofield PM, Kelly F, Cheeseman K, Mitchinson MJ. Randomized controlled vitamin E trial in coronary disease patients: Cambridge Heart Antioxidant Study (CHAOS). Lancet. 2016;347:781-6.

Boaz M, Smetana S, Weinstein T, Matas Z, Gafter U, Iaina A et al. Secondary prevention with antioxidants of cardiovascular disease in end-stage renal disease (SPACE): randomized placebo-controlled trial. Lancet 2000;356:1213-8.

GISSI-Prevenzione Investigators. Dietary supplementary with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Lancet. 2000;354:447-55.

Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study investigators. N. Engl. J. Med. 2000;342:145-53.

Michelakis E, Tymchak W, Lien D, Webster L, Hashimoto K, Archer S. Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide. Circulation. 2002;105:2398-403.

Benavides GA, Squadrito GL, Mills RW, Patel HD, Isbell TS, Patel RP et al. Hydrogen sulfide mediates the vasoactivity of garlic Proc Natl Acad Sci USA. 2007;104:17977-82.

Chuah SC, Moore PK, Zhu YZ. S-allyl cysteine mediates cardioprotection in an acute myocardial infarction rat model via a hydrogen sulfide-mediated pathway Am J Physiol Heart Circ Physiol. 2007;293:2693-701.

Esechie A, Kiss L, Olah G, Horvath EM, Hawkins H, Szabo C et al. Protective effect of hydrogen sulfide in a murine model of acute lung injury induced by combined burn and smoke inhalation. Clin Sci. 2008;115:91-7.

Yueqin Z, Xingyue J, Kaili J, Binghe W. Hydrogen sulfide prodrugs—a review, Acta Pharmaceutica Sinica B. 2015;5(5):367-77.

Chattopadhyay M, Kodela R, Nath N, Dastagirzada YM, Velazquez-Martinez CA, Boring et al. Hydrogen sulfide-releasing NSAIDs inhibit the growth of human cancer cells: a general property and evidence of a tissue type-independent effect Biochem Pharmacol. 2012;83:715-22.

Zhao Y, Wang H, Xian M. Cysteine-activated hydrogen sulfide (H2S) donors. J Am Chem Soc. 2011;133:15-7.

Pan J. NO Devarie-Baez and M. Xian Facile amide formation via S-nitrosothioacids Org Lett. 2011;13:1092-4.

Zaorska E, Tomasova L, Koszelewski D, Ostaszewski R, Ufnal M. Hydrogen Sulfide in Pharmacotherapy, Beyond the Hydrogen Sulfide-Donors. Biomolecules. 2020;10(2):323.

Zhao K, Li S, Wu L, Lai C, Yang G. Hydrogen Sulfide Represses Androgen Receptor Transactivation by Targeting at the Second Zinc Finger Module. J Biol Chem. 2014;289:20824-35.

Nadiminty N, Tummala R, Liu C, Yang J, Lou W, Evans CP et al. NF-B2/p52 Induces Resistance to Enzalutamide in Prostate Cancer: Role of Androgen Receptor and Its Variants. Mol Cancer. 2013;12:1629-37.

Poss KD, Tonegawa S. Reduced stress defense in haem oxygenase 1-deficient cells. Proc Natl Acad Sci. 2010;94:10925-30.

Motterlini R, Otterbein LE. The therapeutic potential of carbon monoxide. Nat Rev Drug Discov. 2010;9(9):728-43.

Pamplona A, Ferreira A, Balla J, Jeney V, Balla G, Epiphanio S et al. Haem oxygenase-1 and carbon monoxide suppress the pathogenesis of experimental cerebral malaria. Nature Med. 2007;13:703-10.

Cepinskas G, Katada K, Bihari A, Potter RF. Carbon monoxide liberated from carbon monoxide releasing molecule CORM-2 attenuates inflammation in the liver of septic mice. Am J Physiol Gastrointest Liver Physiol. 2008;294:184-91.

Mizuguchi S, Stephen J, Bihari R, Markovic N, Suehiro S, Capretta A et al. CO-releasing molecule (CORM-3)- derived CO modulates neutrophil (PMN) migration across vascular endothelium by reducing the levels of cell surface-bound elastase. Am J Physiol Heart Circ Physiol. 2009;297:920-9.

Tang XD, Xu R, Reynolds MF, Garcia ML, Heinemann SH, Hoshi T et al. Haem can bind to and inhibit mammalian calcium-dependent Slo1 BK channels. Nature. 2020;425:531-5.

Wegiel B, David J, Kathleen G, Jenny M, Brett O, Beek Y et al. Nitric oxide-dependent bone marrow progenitor mobilization by carbon monoxide enhances endothelial repair after vascular injury. Circulation. 2010;121:537-48.

Zuckerbraun BS, Chin BY, Wegiel B, Billiar TR, Czsimadia E, Rao J et al. Carbon monoxide reverses established pulmonary hypertension. J Exp Med. 2019;203:2109-19.

Miller C, Miller M, McMullin B, Regev G, Serghides L, Kain K et al. A phase I clinical study of inhaled nitric oxide in healthy adults. J Cyst Fibros. 2012;11(4):324-31.

Auler Júnior JO, Carmona MJ, Bocchi EA, Bacal F, Fiorelli AI, Stolf NA et al. Low doses of inhaled nitric oxide in heart transplant recipients. J Heart Lung Transplant. 2016;15(5):443-50.




How to Cite

Natarajan, A., & G., J. W. (2023). Gasotransmitters: a review. International Journal of Basic & Clinical Pharmacology, 12(4), 607–615.



Review Articles